悦康药业集团股份有限公司2026年第一次临时股东会决议公告

Group 1 - The first extraordinary general meeting of shareholders for 2026 was held on February 6, 2026, at the company's innovation drug internationalization industrial park in Beijing [2] - The meeting was convened by the board of directors and chaired by Chairman Wei Shi, utilizing a combination of on-site and online voting methods [2][3] - All procedures for convening and conducting the meeting, as well as the qualifications of attendees and voting procedures, complied with the Company Law and the company's articles of association [2][6] Group 2 - The only resolution discussed was regarding the expected daily related party transactions for 2026, which was approved by more than half of the valid voting rights held by shareholders present at the meeting [4][5] - Related shareholders abstained from voting on the resolution, and separate counting for minority investors was conducted [6] - The meeting was witnessed by lawyers from Beijing Tianchi Juntai Law Firm, who confirmed that all procedures and voting results were legal and valid [6]